Elsa Solà

Elsa Solà

Auto-generated profile, based on publicly available information

Elsa Solà

Liver Unit, IDIBAPS, CIBEReHD, Faculty of Medicine and Health Sciences, Hospital Clinic of Barcelona University of Barcelona Barcelona Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2017 in Gut
Verified
Journal Article
Open access
RHRuben Hernaez
Ruben Hernaez
ESElsa Solà
Elsa Solà
RMRichard Moreau
Richard Moreau
PGPere Ginès
Pere Ginès
Acute-on-chronic liver failure (ACLF) is a syndrome characterised by acute decompensation of chronic liver disease associated with organ failures and high short-term mortality. Alcohol and chronic viral hepatitis are the most common underlying liver diseases. Up to 40%–50% of the cases of ACLF have no identifiable trigger; in the remaining patients, sepsis, active alcoholism and relapse of chronic viral hepatitis are the most common reported precipitating factors. An excessive systemic inflammatory response seems to play a crucial role in the development of ACLF. Using a liver-adapted sequential organ assessment failure score, it is possible to triage and prognosticate the outcome of patients with ACLF. The course of ACLF is dynamic and changes over the course of hospital admission. Most of the patients will have a clear prognosis between day 3 and 7 of hospital admission and clinical decisions such as evaluation for liver transplant or discussion over goals of care could be tailored using clinical scores. Bioartificial liver support systems, granulocyte-colony stimulating factors or stem-cell transplant are in the horizon of medical care of this patient population; however, data are too premature to implement them as standard of care.

20 December 2011 in Hepatology
Verified
Journal Article
Open access
PDF file
JFJavier Fernández
Javier Fernández
JAJuan Acevedo
Juan Acevedo
MCMiriam Castro
Miriam Castro
OGOrlando Garcia
Orlando Garcia
CLCarlos Rodríguez de Lope
Carlos Rodríguez de Lope
VAVicente Arroyo
Vicente Arroyo
Epidemiology, risk factors, and clinical effect of infections by multiresistant bacteria in cirrhosis are poorly known. This work was a prospective evaluation in two series of cirrhotic patients admitted with infection or developing infection during hospitalization. The first series was studied between 2005 and 2007 (507 bacterial infections in 223 patients) and the second between 2010 and 2011 (162 bacterial infections in 110 patients). In the first series, 32% of infections were community acquired (CA), 32% healthcare associated (HCA), and 36% nosocomial. Multiresistant bacteria (92 infections; 18%) were isolated in 4%, 14%, and 35% of these infections, respectively ( P < 0.001). Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL- E ; n = 43) was the main multiresistant organism identified, followed by Pseudomonas aeruginosa (n = 17), methicillin-resistant Staphylococcus aureus (n = 14), and Enterococcus faecium (n = 14). The efficacy of currently recommended empirical antibiotic therapy was very low in nosocomial infections (40%), compared to HCA and CA episodes (73% and 83%, respectively; P < 0.0001), particularly in spontaneous bacterial peritonitis, urinary tract infection, and pneumonia (26%, 29%, and 44%, respectively). Septic shock (26% versus 10%; P < 0.0001) and mortality rate (25% versus 12%; P = 0.001) were significantly higher in infections caused by multiresistant strains. Nosocomial origin of infection (hazard ratio [HR], 4.43), long-term norfloxacin prophylaxis (HR, 2.69), recent infection by multiresistant bacteria (HR, 2.45), and recent use of β-lactams (HR, 2.39) were independently associated with the development of multiresistant infections. Results in the second series were similar to those observed in the first series. Conclusions : Multiresistant bacteria, especially ESBL-producing Enterobacteriaceae , are frequently isolated in nosocomial and, to a lesser extent, HCA infections in cirrhosis, rendering third-generation cephalosporins clinically ineffective. New antibiotic strategies tailored according to the local epidemiological patterns are needed for the empirical treatment of nosocomial infections in cirrhosis. (Hepatology 2012)

1 April 2020 in Journal of Hepatology
Verified
Journal Article
Closed access
RMRichard Moreau
Richard Moreau
JCJoan Clària
Joan Clària
FAFerran Aguilar
Ferran Aguilar
FFFrançois Fenaille
François Fenaille
JLJuan Jose Lozano
Juan Jose Lozano
PAPaolo Angeli
Paolo Angeli

1 February 2011 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
MMMarta Martín–Llahí
Marta Martín–Llahí
MGMónica Guevara
Mónica Guevara
ATAldo Torre
Aldo Torre
CFClaudia Fagundes
Claudia Fagundes
TRTea Restuccia
Tea Restuccia
PGPere Ginès
Pere Ginès

1 September 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
CFClaudia Fagundes
Claudia Fagundes
RBRogelio Barreto
Rogelio Barreto
MGMónica Guevara
Mónica Guevara
EGElisabet Garcia
Elisabet Garcia
ESElsa Solà
Elsa Solà
PGPere Ginès
Pere Ginès

1 August 2012 in Journal of Hepatology
Verified
Journal Article
Closed access
CFClaudia Fagundes
Claudia Fagundes
MPMarie-Noëlle Pépin
Marie-Noëlle Pépin
MGMónica Guevara
Mónica Guevara
RBRogelio Barreto
Rogelio Barreto
GCGregori Casals
Gregori Casals
PGPere Ginès
Pere Ginès